ImmunityBio Inc. shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...
Stocktwits on MSN
IBRX stock is back: Anktiva now targets severe pneumonia after clearing key checkpoint in bladder cancer trial
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
SurvivorNet on MSN
Muscle invasive bladder cancer: Understanding your treatment options
Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results